2011 ACRIN Annual Meeting Proposal for facilitating protocol development and site pre-activation Suzanne L. Palmer, M.D. Tammie Possemato Chaan Ng, M.D.

Slides:



Advertisements
Similar presentations
Commission on Cancer Mission
Advertisements

Every Womans Life PROGRAM MANUAL UPDATE
CURRENT STATE OF LIVER ALLOCATION AND DISTRIBUTION John R. Lake, MD University of Minnesota Medical School.
Pathway Planning – a model for study initiation or troubleshooting.
ACRIN 6698 Protocol: Diffusion-weighted MR Imaging Biomarkers for Assessment of Breast Cancer Response to Neoadjuvant Treatment: A sub-study of the ISPY-2.
2011 ACRIN Annual Meeting Washington University, PIs: Pamela Woodard, M.D. Tammie Benzinger, M.D. Hypothesis: Availability of a coordinator and technologist.
ACRIN 6673 MULTICENTER FEASIBILITY STUDY OF PERCUTANEOUS RADIOFREQUENCY ABLATION OF HEPATOCELLULAR CARCINOMA IN CIRRHOTIC PATIENTS Final Report from Central.
Michael Birrer, PI, Director, Gynecologic Medical Oncology, MGH Lari Wenzel, Co-PI, Prof. of Medicine, University of California, Irvine
Research Protocol ACRIN 6678 Learning About PET/CT Scans: Can PET/CT scans provide helpful information for the treatment of non-small cell lung cancer?
Consent for Research Study A study for patients newly diagnosed with advanced glioblastoma (brain cancer): Learning whether a PET scan with F-fluoromisonidazole.
ACRIN 6687 A Phase 2, Multicenter Evaluation of 18 F-Fluoride PET as a Pharmacodynamic Biomarker for Dasatinib, a Src Kinase Inhibitor, in Men With Castration-Resistant.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence January–February 2011.
Ilana F. Gareen, Ph.D. Brown University Center for Statistical Sciences
The Recipient Experience Jaime Myers, RN, MSN, CCTC April 29, 2011.
ACRIN 6657/CALGB Consent for Research Study Contrast-Enhanced Breast MRI and MRS: A Correlative Science Studies to Characterize Tumor Response in.
SYNOPSIS OF THE PROTOCOL Title: Pregnancy Associated Breast Cancer (PABC); Prospective Data Registry in Saudi Arabia Sponsor: Oncology Department, King.
ACRIN Abdominal Committee ACRIN Gynecologic Committee Fall Meeting 2010.
Consent for Research Study A study for patients with a diagnosis of liver cancer who are on the waiting list for a liver transplant Comparison of advanced.
ACRIN Research Associates Educational Session Radiation Therapy Oncology Group Research Associates Committee Joyce Neading, RHIT, CTR Program Director,
Caveats We are interpreting the guidelines along with you We may have some limited additional insight due to participation during the course of planning.
ACRIN 6678 Site Training ACRIN 6678 FDG-PET/CT as a Predictive Marker of Tumor Response and Patient Outcome: Prospective Validation in Non-small Cell Lung.
Annual Meeting 2011 Clinical Trial Development Clinical Trial Development: OEWG, RA’s Role, and Activating Trials on Deadline Martha Heckel Protocol Associate.
ACRIN 6673 Percutaneous Radiofrequency Ablation of Hepatocellular Carcinoma in Cirrhotic Patients: A Multi-Center Study.
A Phase II Study to Evaluate the Safety and Toxicity of Sparing Radiation to the Pathologic N0 Side of the Neck in Squamous Cell.
2011 ACRIN Annual Meeting ACRIN ACCELERATED ACCRUAL DEMONSTRATION PROJECT Department of Radiology The University of Iowa Carol Mertens, Ph.D., CFLE, LMHC.
Organized Diagnostic Assessment Demonstration Projects Organized Diagnostic Assessment Demonstration Projects Grand River Regional Diagnostic Assessment.
Clinical Trial Designs An Overview. Identify: condition(s) of interest, intended population, planned treatment protocols Recruitment of volunteers: volunteers.
ACRIN 6678 Site Training ACRIN 6678 FDG-PET/CT as a Predictive Marker of Tumor Response and Patient Outcome: Prospective Validation in Non-small Cell Lung.
ACRIN 6682 Phase II Trial of 64 Cu-ATSM PET/CT in Cervical Cancer Principal Investigator: Farrokh Dehdashti, MD 10/2/09.
2011 ACRIN Annual Meeting The ACRIN Accrual Project at University of Washington Constance Lehman, MD. PhD David Mankoff, MD. PhD Tiffany Wong, MS.
ACRIN 6685 Overview ACRIN 6685 A Multi-center Trial of FDG-PET/CT Staging of Head and Neck Cancer and its Impact on the N0 Neck Surgical Treatment in Head.
ACRIN 6682 Phase II Trial of 64 Cu-ATSM PET/CT in Cervical Cancer Principal Investigator: Farrokh Dehdashti, MD 9/30/10.
Building Clinical Infrastructure and Expert Support Michael Steinberg, MD, FACR ULAAC Disparity Project Centinela/Freeman Health System.
SARC: Participation and Protocol / Concept Review Robert Maki, MD PhD Memorial Sloan-Kettering Cancer Center.
Consent for Research Study A study for patients newly diagnosed with advanced glioblastoma (brain cancer): Learning whether a PET scan with F-fluoromisonidazole.
OPTN Liver and Intestinal Organ Transplantation Committee Update Spring 2012 Kim Olthoff, MD, Chair David Mulligan, MD, Vice-chair.
American College of Radiology Imaging Network ACRIN 6664 ACRIN 6664 – Protocol Review The National CT Colonography Trial Name(s) of presenters.
How To Design a Clinical Trial
ACRIN 6666 Follow-Up 0 month “12 month” = months –If patient has been contacted, plans follow-up, please hold IA, IS, and F1 until she returns (even.
Enrollment and Monitoring Procedures for NCI Supported Clinical Trials Barry Anderson, MD, PhD Cancer Therapy Evaluation Program National Cancer Institute.
Introduction Organ Transplantation Program Update Advisory Committee on Organ Transplantation November 17, 2015 Melissa Greenwald, MD Acting Director Division.
David A. Gerber, MD Professor and Chief Division of Abdominal Transplantation Department of Surgery University of North Carolina at Chapel Hill.
Biostatistics and Data Management Center 22 January 2016 Report from the Biostatistics and Data Management Center Constantine Gatsonis, PhD ACRIN Biostatistics.
ACRIN 6682 Phase II Trial OF 64 Cu-ATSM PET/CT in Cervical Cancer Principal Investigator: Farrokh Dehdashti, MD 10/4/08.
2011 ACRIN Annual Meeting ACRIN Accrual Committee ACRIN 2011 Fall Meeting Reginald F. Munden.
AccrualNet: A New NCI Tool for Supporting Accrual to Clinical Trials Linda Parreco, RN, MS NCI, Office of Communication and Education September 29, 2010.
NCCCP Pilot – Clinical Trials Ann O’Mara, PhD, RN, FAAN Program Director Community Clinical Oncology Program Division of Cancer Prevention June 26, 2007.
Florida Cancer Plan Phil Roland, MD FACS FACOG Florida State Chair A Commission on Cancer.
SARC018: A SARC PILOT MULTICENTER STUDY OF PREOPERATIVE RADIATION AND SURGERY IN PATIENTS WITH HIGH- RISK DESMOID TUMORS Robert S. Benjamin, M.D.
Performing a Successful Supportive Care Clinical Trial Jennifer Temel, MD.
The Diabetic Retinopathy Clinical Research Network
ACOSOG Sarcoma Committee Chair: Peter W.T. Pisters, MD Vice Chairs: Edward Cheng, MD (Orthopedic Oncology) Robert Maki, MD, PhD (Medical Oncology) Brian.
ELIGIBILITY CRITERIA- Summarised
S1400 Revisions #4/5 Training Slides
TMIST A Breast Cancer Screening Trial
How To Design a Clinical Trial
National Liver Review Board (NLRB)
Pediatric Transplantation Committee
CLINICAL PROTOCOL DEVELOPMENT
The Recipient Experience
BREAST CANCER ONCOLOGY NAVIGATION SERVICE
Coordination (benign lesions)
Liver Transplantation: 50 years
Learning About PET/CT Scans:
Liver Transplant For Patients with PSC
Changes to HCC Criteria for Auto Approval
The BAHNO Head & Neck Cancer Surveillance Audit 2018
The BAHNO Head & Neck Cancer Surveillance Audit 2018
Proposal to Delay the HCC Exception Score Assignment
SYNOPSIS OF THE PROTOCOL
Presentation transcript:

2011 ACRIN Annual Meeting Proposal for facilitating protocol development and site pre-activation Suzanne L. Palmer, M.D. Tammie Possemato Chaan Ng, M.D. Sujaya Rao Michelle Haynes ACRIN Accelerated Accrual Demonstration Project: Univ. of Southern California and MD Anderson Collaboration

2011 ACRIN Annual Meeting #1 Protocol development phase #2 Site pre-activation phase

2011 ACRIN Annual Meeting #1 Protocol development phase Brief Study Summary –Schema –Study objectives and end points –Patient eligibility and enrollment –Associated therapy or tissue biomarker studies –Imaging and equipment requirements –Minimum imaging requirements –Timeline for required imaging –Information needed for the sites to evaluate recruitment potential –Clinical services involved –Study schedule –Reimbursement

2011 ACRIN Annual Meeting #2 Site pre-activation phase Individual site assessment Performed by RA and/or PI Step-by-step –Review of the brief study summary –Assess study requirements and match to site’s resources –Estimate patient recruitments The Mock Screen –Identify radiology department personnel and conferences –Identify referring clinicians and coordinators –Identify tumor boards and other sources of patient recruitment If the site assessment is successful, the activation and recruitment phases should go more rapidly.

2011 ACRIN Annual Meeting #2 Site pre-activation phase Individual site assessment Performed by RA and/or PI Step-by-step –Review of the brief study summary –Assess study requirements and match to site’s resources –Estimate patient recruitments The Mock Screen –Identify radiology department personnel and conferences –Identify referring clinicians and coordinators –Identify tumor boards and other sources of patient recruitment If the site assessment is successful, the activation and recruitment phases should go more rapidly.

2011 ACRIN Annual Meeting #2 Site pre-activation phase Individual site assessment Performed by RA and/or PI Step-by-step –Review of the brief study summary –Assess study requirements and match to site’s resources –Estimate patient recruitments The Mock Screen –Identify radiology department personnel and conferences –Identify referring clinicians and coordinators –Identify tumor boards and other sources of patient recruitment If the site assessment is successful, the activation and recruitment phases should go more rapidly.

2011 ACRIN Annual Meeting #2 Site pre-activation phase Individual site assessment Performed by RA and/or PI Step-by-step –Review of the brief study summary –Assess study requirements and match to site’s resources –Estimate patient recruitments The Mock Screen –Identify radiology department personnel and conferences –Identify referring clinicians and coordinators –Identify tumor boards and other sources of patient recruitment If the site assessment is successful, the activation and recruitment phases should go more rapidly.

2011 ACRIN Annual Meeting #2 Site pre-activation phase Individual site assessment Performed by RA and/or PI Step-by-step –Review of the brief study summary –Assess study requirements and match to site’s resources –Estimate patient recruitments The Mock Screen –Identify radiology department personnel and conferences –Identify referring clinicians and coordinators –Identify tumor boards and other sources of patient recruitment If the site assessment is successful, the activation and recruitment phases should go more rapidly.

2011 ACRIN Annual Meeting Data extraction capability: Examples of sample tables: Important information for the ACRIN Study Group Site numberPI name/contactRA name/contactTarget pop available Inc/excl feasible Interest in participating Why no? 4206Jeffrey Brody Wendy Smith yes noDon’t have the time 4567Ronald McDonald Hamburglar no yes 4317Suzanne Palmer Tammie Possemato yesno Site not participating in GOG 0262 Protocol #: 6695 ACRIN PI: Chaan Ng ACRIN project manager: Bernadine Dunning Site numberEstimated # of patients 42062/ month 45670/month 43171/month

2011 ACRIN Annual Meeting Protocol#: 6690 ACRIN PI: Christoph Wald ACRIN project manager: Donna Hartfeil Data extraction capability: Different forms/format examples: Important information for the Study Site SourceTime/LocationContactClinical Services Attending Liver tumor boardTuesday/wk/ 2pm - UHJennifer Pena UNOS Websitehttps://portal.unos.orgPassword ACRIN 6690 SITE PERSONNEL OVERVIEW RADIOLOGY: P.I. Suzanne Palmer /Phone #: Responsibilities: PI responsible for all aspects of the RA Tammie Possemato /Phone #: Responsibilities: Assists PI with all aspects of study. CLINICAL SERVICES: Abdominal Transplant John Donovan Address: Responsibilities: Access to UNOS database, ordering of UNOS recertification CT 90 days. UNOS Contact: Jennifer Pena Address: Responsibilities: Notification of MELD Listing Pathology Lydia Petrovich Address: Responsibilities: Comparison of imaging to explant. Oncology: Anthony ElKhoureiy Address: Responsibilities: Patient referral Surgery: Yuri Genyk Address: Responsibilities: Patient referral PATIENT IDENTIFICATION/RECRUITMENT SOURCES:

2011 ACRIN Annual Meeting Data extraction capability: Different forms/format examples: Important information for the Study Site STUDY SUMMARY ACRIN Study #: 6690 ACRIN Study Name: Comparison of multiphase contrast-enhanced CT and MRI for diagnosis of HCC and liver transplant allocation Study Contact Information : ACRIN PI: Christoph Wald, MD, Ph.D, ACRIN Project Manager: Donna Hartfeil, , Site Number: 4317 Site PI: Suzanne Palmer, M.D., , Site RA: Tammie Possemato, , ACRIN Schema: Study objectives and end points: The main objective of the ACRIN 6690 trial is to compare modern multiphase contrast-enhanced CT and MRI with pathologic liver findings to establish the performance characteristics of these imaging modalities to accurately detect, diagnose, and stage HCC in patients with chronic liver disease. The CT and MRI examinations acquired within 90 days of transplantation will be compared with the explant pathology findings. The primary analysis will compare CT to MRI results at the lesion level using core laboratory interpretations of the imaging studies; secondary analysis will be performed at the patient level. Patient eligibility: Patients diagnosed with HCC and listed for liver transplant surgery with priority MELD (Model for End-Stage Liver Disease) points based on their cancer diagnosis will participate. Eligible patients include those who may be waiting for a liver to become available from a deceased donor or be scheduled to undergo a living donor adult liver transplant. Patients must enroll in the trial within 30 days after initial listing with HCC- exception points to the United Network for Organ Sharing (UNOS) waitlist. Basic protocol: Each site will image a participant with CT or MRI approximately every 90 days (or earlier) per the OPTN/UNOS HCC-exception point update requirements for their region. This imaging to evaluate disease is considered standard of care. This research trial requires that complement imaging (CT or MRI, whichever imaging was not done as the standard of care) be completed at each 90-day interval. This imaging must be completed within 7 days of the standard-of-care imaging for that time interval. The goal is to compare the CT and MRI examinations acquired within 90 days of transplantation with explant pathology findings. Should a participant undergo local ablative therapy, CT and MRI should be completed no less than 28 days and no more than 60 days after each completed ablative therapy scheme. Enrollment: A total of 440 participants will be accrued to the ACRIN 6690 trial. Number per site was not included in available protocol

2011 ACRIN Annual Meeting Significant outcomes, to date: USC results using our tool USC Study Accrual (as of 9/15) Problems Identified through Mock Screen Solutions/Outcomes Difficulty identifying potential patients; multiple competing studies; oncology in charge of study assignment and interested in accruing to competing studies Change in PI. Tumor boards identified and attended; contact made with referring MD’s; potential patients identified at conferences Difficulty identifying potential patients; disinterested PI; no communication with clinical services; requirements for imaging not reviewed for access to radiotracer and equipment needs Added PI with interest in gynecologic imaging; regular attendance at weekly tumor boards; imaging road blocks identified and resolved Difficulty identifying patients for study; potential patients not interested in participating due to QOL questionnaire; inclusion criteria for N0 neck not well defined; reimbursement inadequate Working with clinical MD’s to recruit patients from clinic and tumor boards; working with ACRIN for clarification of eligibility; attempt to convince USC to drop tithing for this study Difficulty identifying patients for study; multiple competing studies; failure of RA to follow-up on patients identified in tumor boards. Replaced recruiting RA Timing for patient recruitment critical. Knowledge of MELD exception application and any scheduled or completed treatment. RA at weekly conference where patients are listed for MELD exception, and recruited to study with clinical support. One of the first 10 sites to open.

2011 ACRIN Annual Meeting And finally………. Congratulations to Tammie Possemato for being honored as the recipient of the Jo-Ann D’Amato Award!